URGN Stock Analysis: Buy, Sell, or Hold?
URGN - UroGen Pharma Ltd. Ordinary Shares
$35.42
0.27 (0.77%)
▲
5d:
+10.86%
30d:
+22.6%
90d:
+100.57%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When URGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: URGN is 9.4% above its trading range ($32.38). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: URGN is 9.4% above its trading range ($32.38). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.67
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$22.77
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: URGN is currently trading at $35.42, which is considered extended relative to its 30-day fair value range of $27.12 to $32.38. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.8) compared to its historical average (21.3). At these levels, the market is pricing in 10.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is approaching resistance at $36.08. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: URGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, URGN is in a strong uptrend. The price is approaching resistance at $36.08. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: URGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$27.12 -
$32.38
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.8%
Protect Your Profits
URGN is technically overbought (RSI 77). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+9.4% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($36.88)
- NEUTRAL: Trading at premium valuation - market expects 10.7% growth which is achievable
- CAUTION: Extended 9.4% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$27.12 -
$32.38
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$4.15
(11.7%)
Support & Resistance Levels
Support Level
$27.81
Resistance Level
$36.08
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.82
Wall Street Target
$36.88
(+4.1%)
Revenue Growth (YoY)
151.6%
Profit Margin
-94.8%
Valuation Premium vs History
+10.7% premium
PE vs Historical
28.8 vs 21.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+10.7%
(market-implied from PE analysis)
1-Year Target
$39.21
(+11%)
2-Year Target
$43.41
(+23%)
3-Year Target
$48.05
(+36%)
3-Yr Target (if PE normalizes)
(PE: 29→21)
PE COMPRESSION
$35.51
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 25, 2026 2:17 AM ET
Data refreshes hourly during market hours. Next update: 3:17 AM
Data refreshes hourly during market hours. Next update: 3:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is URGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason Drew Smith
SELL
7479 shares
2026-02-03
Mark Schoenberg
SELL
7373 shares
2026-02-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 61 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
Advanced URGN Option Strategies
Professional options setups generated by AI based on today's URGN price and gamma walls.
